Pregabaline, a second generation antiepileptic, is marketed in France since 2005. It is also indicated in the treatment of painful neuropathy and in generalized anxious disorder. Its pharmacokinetic profile: low metabolism and no binding to plasma proteins, is not in favour of the necessity of a TDM. But other studies would be necessary to concluded more definitively. Pregabalin however, required a dosage adjustment in case of renal insufficiency. The values of the plasma concentrations found after various doses are in agreement in the different studies, without that we can define a therapeutic range. For this molecule, the level of proof of the interest of TDM was estimated in: remaining to estimate.
Keywords: Pregabalin; Prégabaline; monitoring; pharmacologique; suivi thérapeutique; therapeutic drug.
Copyright © 2010 Société Française de Pharmacologie et de Thérapeutique. Publié par Elsevier Masson SAS.